Investigators from the Cleveland Clinic Cole Eye Institute, Cleveland, reported the results of a study that identified macular structural and vascularity changes in adults who had been born ...
A new study of Chinese children and adults reported that investigated the effects of progression of myopia found that over the course of 10 years the best-corrected visual acuity (BCVA) and the visual ...
Home-stored anti-VEGF drugs face risks from temperature changes, pointing to a need to protect efficacy and avoid dangerous contamination. A European study found that temperature changes have the ...
The 1-year results from the HELIOS Trial that evaluated the investigational intravitreal Axitinib implant (OTX-TKI, Ocular Therapeutix) for the treatment of non-proliferative diabetic retinopathy ...
Panelists discuss how patients experiencing frequent anti-VEGF treatment burdens with 4- to 8-week intervals between injections are ideal candidates for PDS as an alternative delivery method.
The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa. Clinical stage biopharmaceutical company Nacuity ...
Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard ...
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration. InflammX Therapeutics, Inc. has entered into an option agreement granting ...